Forte Biosciences Inc (FBRX)
$0.7386
+0.02
(+2.58%)▲
Insights on Forte Biosciences Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 80.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 345.2%
Performance
- $0.71$0.77$0.74
4.05%
Downside
Day's Volatility :7.43%
Upside
3.52%
- $0.38$1.15$0.74
48.65%
Downside
52 Weeks Volatility :66.96%
Upside
35.65%
Returns
| Period | Forte Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 5.67% | 1.9% | 0.0% |
6 Months | 46.75% | 10.7% | 0.0% |
1 Year | -29.66% | 4.6% | -1.1% |
3 Years | -97.97% | 14.2% | -22.1% |
Highlights
Market Capitalization | 26.2M |
Book Value | $0.97 |
Earnings Per Share (EPS) | -1.0 |
Wall Street Target Price | 2.88 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -50.15% |
Return On Equity TTM | -84.92% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -32.5M |
Diluted Eps TTM | -1.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.56 |
EPS Estimate Next Year | -0.43 |
EPS Estimate Current Quarter | -0.28 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 289.93%
Technicals Summary
Sell
Neutral
Buy
Forte Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Forte Biosciences Inc | 4.03% | 46.75% | -29.66% | -97.97% | -99.42% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Forte Biosciences Inc | NA | NA | NA | -0.56 | -0.85 | -0.5 | NA | 0.97 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Forte Biosciences Inc | Buy | $26.2M | -99.42% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Institutional Holdings
Tybourne Capital Management (HK) Ltd
9.96%Perceptive Advisors LLC
8.97%Bvf Inc
8.19%Cable Car Capital LLC
5.58%Fred Alger Management, LLC
5.05%Farallon Capital Management, L.L.C.
4.97%
Corporate Announcements
Forte Biosciences Inc Earnings
Forte Biosciences Inc’s price-to-earnings ratio stands at None
Read More
Company Information
we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. at the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (rrvs), which are designed to selectively deliver therapeutic genes into the dna of cancer cells. our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. in other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ he
Organization | Forte Biosciences Inc |
Employees | 9 |
CEO | Dr. Paul A. Wagner Ph.D. |
Industry | Health Technology |
